Vir Biotechnology Inc (VIR) Stock Price, Quote & News

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 906 4324

Website: www.vir.bio

Address:

1800 Owens Street, Suite 900, San Francisco, United States

VIR_Tical1 Oct. 27 at 7:26 PM

$VIR Update: https://tipranks.onelink.me/WJho/lylvv6on

1 · Reply

Dunnieboy1 Oct. 26 at 5:53 PM

$VIR Arch Venture Fund IX, L.P.: This is a 10% owner and holds about 28,666,663 shares. Arch Venture Partners, L.P.: Holds approximately 12,916,663 shares, or about 9.30% of the company. ARCH Venture Partners IX LP: Holds 5,626,008 shares, or about 4.05%. Arch Venture Fund IX Overage, L.P.: Holds 7,290,655 shares, or about 5.25%.

0 · Reply

Dunnieboy1 Oct. 26 at 5:45 PM

$VIR how come Arch Ventures purchase about 15-20% of Vir’s shares without informing the Nasdaq, they could only have purchased them from a institutional holder or direct from Vir. I don’t know of any institution with such a large stake, Vir got consent to issue more shares via a ’mixed shelf offering’ so they could have purchased them direct & although this would cause some dilution it would be offset by Vir banking $65M. My point is why hasn’t the purchase be announced via the stock exchange, any stake over i think 3% requires notification. Arch could own over 20% now.

0 · Reply

Dunnieboy1 Oct. 26 at 1:36 AM

$VIR Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners ... Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), ...

0 · Reply

Dunnieboy1 Oct. 26 at 1:35 AM

$VIR my previous posts taken from marketbeat are the most exciting i’ve read about Vir in a long time. Robert Nelson set up Arch Ventures Management Ltd to invest in start up biotech co’s & if they have invested a ’further’ $65,100,000 then there must be positive news coming.

0 · Reply

big_dipper1546 Oct. 26 at 1:23 AM

$VIR rate cut is supposed to be bullish for biotech. Could be normal capital deployment and allocation. Nothing to do with fundamentals.

0 · Reply

Dunnieboy1 Oct. 26 at 1:18 AM

$VIR Sato serves both Vir & Arch & is in fact a ’venture partner’ at Arch who have invested $65,100,000 in Vir. Vicki Sato, Ph.D., has served as Chairman of our Board since December 2016. Dr. Sato is currently a venture partner at ARCH Venture Partners, Chairman of the Board at Denali Therapeutics, a member of the board of directors of Allogene Therapeutics, Inc. and a member of the National Academies of Sciences, Engineering and Medicines’ Committee on Science, Technology and Law. In addition, she served on President Biden’s Council of Advisors in Science and Technology (PCAST) from 2021 to 2025.

0 · Reply

Dunnieboy1 Oct. 26 at 1:09 AM

$VIR with regard to my previous postings, Arch Ventures are the founder investors in Vir we have directors who serve on both companies boards, Vicki Sato our chairman for one, Sato also has major stakes in Arch & Vir. Something big is coming if Arch have invested a further $65,000,000 in Vir.

0 · Reply

Dunnieboy1 Oct. 26 at 1:01 AM

$VIR https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-major-shareholder-endurance-cayman-ltd-svf-sells-154383-shares-2025-10-24/

0 · Reply

Dunnieboy1 Oct. 26 at 12:16 AM

$VIR A-numbe of institutional investors have recently modified their holdings of the company. ARCH Venture Management LLC bought a new stake in Vir Biotechnology during the second quarter worth about $65,100,000. Orbimed Advisors LLC raised its holdings in Vir Biotechnology by 5.9% during the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company's stock worth $11,999,000 after acquiring an additional 132,466 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Vir Biotechnology by 9.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company's stock worth $8.X,909,000 after acquiring an additional 122,219 shares in the last quarter. Aberdeen Group plc raised its holdings in Vir Biotechnology by 45.3% during the second quarter. Aberdeen Group plc now owns 1,006,891 shares of the company's stock worth $5,075,000 after acquiring an additional 313,699 shares in the last quart

1 · Reply

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 4:05 PM EDT - 18 days ago

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Oct 7, 2025, 8:00 AM EDT - 21 days ago

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Sep 16, 2025, 1:15 PM EDT - 5 weeks ago

Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 6, 2025, 11:01 PM EDT - 2 months ago

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 8:05 AM EDT - 2 months ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 3 months ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 24, 2025, 8:05 AM EDT - 3 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 23, 2025, 12:10 PM EDT - 3 months ago

Vir Biotechnology: Hep B And Cancer Projects March On

Jul 22, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:00 AM EDT - 4 months ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

May 28, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 20, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 12, 2025, 4:05 PM EDT - 6 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 9, 2025, 6:00 AM EDT - 6 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 8, 2025, 3:37 PM EDT - 6 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 7, 2025, 11:21 PM EDT - 6 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 6 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 6 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 24, 2025, 9:30 AM EDT - 6 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Mar 21, 2025, 7:10 AM EDT - 7 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 13, 2025, 8:05 AM EDT - 8 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Feb 26, 2025, 11:22 PM EST - 8 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 8 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 4:05 PM EST - 8 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:05 PM EST - 9 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 13, 2025, 6:10 PM EST - 10 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 10, 2025, 2:32 PM EST - 10 months ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 9, 2025, 9:00 AM EST - 10 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 8, 2025, 12:28 PM EST - 10 months ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 7:45 AM EST - 10 months ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Dec 18, 2024, 9:30 AM EST - 11 months ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 12:57 PM EST - 11 months ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 12, 2024, 4:05 PM EST - 11 months ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Nov 26, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 25, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 9:15 PM EST - 1 year ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 15, 2024, 11:00 AM EST - 1 year ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 5, 2024, 11:29 AM EST - 1 year ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Oct 31, 2024, 11:12 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Oct 3, 2024, 4:00 PM EDT - 1 year ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 10, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Aug 22, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

VIR_Tical1 Oct. 27 at 7:26 PM

$VIR Update: https://tipranks.onelink.me/WJho/lylvv6on

1 · Reply

Dunnieboy1 Oct. 26 at 5:53 PM

0 · Reply

Dunnieboy1 Oct. 26 at 5:45 PM

0 · Reply

Dunnieboy1 Oct. 26 at 1:36 AM

$VIR Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners ... Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), ...

0 · Reply

Dunnieboy1 Oct. 26 at 1:35 AM

0 · Reply

big_dipper1546 Oct. 26 at 1:23 AM

$VIR rate cut is supposed to be bullish for biotech. Could be normal capital deployment and allocation. Nothing to do with fundamentals.

0 · Reply

Dunnieboy1 Oct. 26 at 1:18 AM

0 · Reply

Dunnieboy1 Oct. 26 at 1:09 AM

0 · Reply

Dunnieboy1 Oct. 26 at 1:01 AM

$VIR https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-major-shareholder-endurance-cayman-ltd-svf-sells-154383-shares-2025-10-24/

0 · Reply

Dunnieboy1 Oct. 26 at 12:16 AM

1 · Reply

Dunnieboy1 Oct. 24 at 8:52 PM

$VIR Softbank offloaded another 298,549 shares, they’re shifting quite a lot of shares at the moment but still have 14,711,635 left. Slightly concerning but someone’s buying them.

0 · Reply

nUme22 Oct. 23 at 7:18 PM

$VIR feels like this is going below 5 soon

0 · Reply

Mhand Oct. 23 at 6:08 PM

$VIR WTF is up this afternoon? Softbank at it again? Who's buying?

1 · Reply

Dunnieboy1 Oct. 22 at 10:06 PM

$VIR Softbank have reported further sales of aprox 220,000 & 109,000 leaving them with just over 15m shares.

1 · Reply

Dunnieboy1 Oct. 22 at 1:07 PM

$VIR Softbank disposed of 834,000 shares, only another 138m shares left. Could be for a variety of reasons but market makers will only take on what they can sell on, they are not stock holders.

1 · Reply

Njdude Oct. 20 at 10:21 PM

$VIR 49 cents on no news ??

0 · Reply

Njdude Oct. 18 at 11:19 PM

$VIR https://abcnews.go.com/amp/Health/wireStory/fda-unveils-drugs-receive-expedited-review-support-national-126598808

0 · Reply

Njdude Oct. 18 at 11:18 PM

$VIR FDA just released 9 drugs that are experimental and VIR was not one of them and 1 was for Hepatitis. Sadness

0 · Reply

Floridahrrcn Oct. 17 at 2:03 PM

$VIR long term holder but what’s up with all insiders selling all the time?

0 · Reply

TheRealShortSqueezy Oct. 16 at 7:15 PM

$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS

2 · Reply

Dunnieboy1 Oct. 15 at 6:35 PM

$VIR released 3hours ago;In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $15.00. The company’s shares opened today at $5.73

1 · Reply

Dunnieboy1 Oct. 15 at 8:57 AM

$VIR Softbank have disposed of around 250,000 shares still leaving them with well over 15m shares.

1 · Reply

Market Cap	830.72M
Revenue (ttm)	74.21M
Net Income (ttm)	-521.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-703.36%
Debt to Equity Ratio	0.00

Volume	985,900
Avg Vol	1,461,764
Day's Range	N/A - N/A
Shares Out	138.92M
Stochastic %K	66%
Beta	1.27
Analysts	Strong Sell
Price Target	$17.22